Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres.

BMC cancer - 26 Oct 2016

Boleij Annemarie, Tack Véronique, Taylor Aliki, Kafatos George, Jenkins-Anderson Sophie, Tembuyser Lien, Dequeker Els, van Krieken J Han

Abstract excerpt

BACKGROUND: Treatment options for patients with metastatic colorectal cancer (mCRC) include anti-epithelial growth factor therapies, which, in Europe, are indicated in patients with RAS wild-type tumours only and require prior mutation testing of "hot-spot" codons in exons 2, 3 and 4 of KRAS and NRAS. The aim of this study was to evaluate the implementation of RAS testing methods and estimate the RAS mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Codon
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mutational Analysis

Share to Europe

Share to Genes, ras

Share to Genetic Testing

Share to Health Care Surveys

Source

Open in PubMed Open full text

Identifiers

PMID: 27784278
DOI: 10.1186/s12885-016-2810-3
PMCID: PMC5080758

Genes

KRAS
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres.PMID 27784278Read ↗

The RAS testing in real world management of metastatic colorectal cancer: The results of Italian Laboratories Survey.Semantic proximity Read ↗

RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data.Semantic proximity Read ↗

RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers.Semantic proximity Read ↗

Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia.Semantic proximity Read ↗

KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?Semantic proximity Read ↗

RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.Semantic proximity Read ↗

Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.Semantic proximity Read ↗

Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide ExperienceSemantic proximity Read ↗

Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal CancerSemantic proximity Read ↗

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal CancerSemantic proximity Read ↗

Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database.Semantic proximity Read ↗

KRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: a retrospective database analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.